Compete in This Year's Start-Up Stadium
Applications for Start-Up Stadium are now closed. We are currently reviewing applications and will be in contact in the coming months as we begin to select our finalists for Boston.
Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2023 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback. Finalists will be eligible for a highly discounted registration rate to attend the 2023 BIO International Convention.
This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category. Past prizes have included 'fast-track' admission review to incubator programs at the Illumina Accelerator and The Innovation Space, as well as complimentary, one-year memberships in the Biotechnology Innovation Organization with access to the cost-savings programs of BIO Business Solutions.
SiVEC Biotechnologies
Fort Collins, Colorado
OncoXome
Los Angeles, California
Thank You to our 2022 Finalists
Thank You to our 2022 Start-Up Stadium Judges
- Orrin Ailloni-Charas, MD, MBA, Managing Partner, Cura Capital
- Christopher Aleong, Chief Business Officer, Lumosa Therapeutics
- John Behr, Partner, SV Health Investors
- James Buxton, Senior Associate, NEA
- Joseph Charalel, Senior Associate, Pivotal bioVenture Partners (US)
- David H. Crean, Managing General Partner, Cardiff Advisory LLC
- Bettina Ernst, Director, BERNINA BioInvest
- David Fox, Co-founder, Modality.ai
- Yinghong Gao, Venture Partner, Viva BioInnovator
- Juliet Gomez, Program Manager, Flinn Foundation
- Gábor Gyülvészi, Sr. Associate, Nextech Invest AG
- Lu Han, Partner, Lumira Ventures
- Daniel Jacobs, Managing Director, Pathway Bioventures
- Scott M. Kahn, PhD, Founder, Alykomed Global Solutions LLC
- Vince Kohli, Global Tech Impact Capitalist, Trillion Ventures Global Capital Fund
- Benjamin Li, Senior Associate, Pivotal bioVenture Partners (US)
- David Malek, Venture Partner, Pivotal bioVenture Partners (US)
- Marc Martin-Casas, Head of Illumina Accelerator, San Francisco, Illumina Accelerator
- Laurie K. McNamara, PhD, Esq., Associate, Wilson Sonsini Goodrich & Rosati
- Miguel A. Mendez, Managing Director, Facultas Partners
- Mariana Mihalusova, Vice President, Venrock
- Sandra Miller, General Partner, Cura Capital
- Graham Mills, Investment Manager, Abingworth LLP
- Ivan Morace, Senior Investment Analyst, MediVentures GmbH
- Anton Neschadim, Senior Advisor, GreenSky Capital
- Younes Ouahid, Partner, Facultas Partners
- William D. Provine, PhD, President & CEO, Innovation Space
- Marcie Reilly, Program Manager, Partnerships & Special Projects, Innovation Space
- Catello Somma, Associate, TVM Capital Life Science Management GmbH
- Lesley Stolz, PhD, VP, Early Innovation Partnering, Johnson & Johnson Innovation
- Nilay Thakar, Principal, ARCH Venture Partners
- Anton Xavier, Director, Early Stage Life Science Banking, SVB
- Kitty Wu, VP, Head of Business Development and Strategy, Fosun Pharma USA
- Samuel Wu, Venture Partner, 7G BioVentures
- Xiangbin Xu, CEO, QLD Biotherapeutics Inc
- Wenping Zhou, Investment Associate, CT innovations
- John Zhu, Founder and President, Mayewell Capital
